Spread of Carbapenem-Resistant Gram-Negatives and Candida auris during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship?

Laura Magnasco 1,*; Malgorzata Mikulska 1,2; Daniele Roberto Giacobbe 1,2; Lucia Taramasso 1; Antonio Vena 1; Chiara Dentone 1; Silvia Dettori 2; Stefania Tutino 2; Laura Labate 2; Vincenzo Di Pilato 3; Francesca Crea 4; Erika Coppo 3,4; Giulia Codda 3; Chiara Robba 5; Lorenzo Ball 3,5; Nicolo’ Patroniti 3,5; Anna Marchese 3,4; Paolo Pelosi 3,5 and Matteo Bassetti 1,2

Abstract: The possible negative impact of severe adult respiratory distress caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (COVID-19) on antimicrobial stewardship and infection control has been postulated, but few real-life data are available. The aim of this study was to report our experience with colonization/infection of carbapenem-resistant Pseudomonas aeruginosa (CRPA), carbapenem-resistant Klebsiella pneumoniae (CR-Kp) and Candida auris among critically ill COVID-19 patients admitted to the intensive care unit (ICU). All COVID-19 patients admitted to the ICUs at San Martino Policlinico Hospital—IRCCS in Genoa, Italy, were screened from 28 February to 31 May 2020. One-hundred and eighteen patients admitted to COVID-19 ICUs were included in the study. Among them, 12 (10.2%) became colonized/infected with CRPA, 6 (5.1%) with C. auris and 2 (1.6%) with CR-Kp. All patients with CRPA received prior treatment with meropenem, and in 11 (91.7%) infection was not preceded by colonization. Four patients (66.7%) developed C. auris candidemia. A significant spread of resistant pathogens was observed among critically ill COVID-19 patients. Dedicated strategies are warranted to prevent horizontal spread and maintain effective antimicrobial stewardship programs in the setting of COVID-19 care.

Keywords: antimicrobial resistance; intensive care; carbapenem-resistance; Candida auris; Klebsiella pneumoniae; Pseudomonas aeruginosa

1. Introduction

Since its first description in Wuhan Province at the end of 2019 [1], severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has scaled to an unprecedented pandemic. Up to a third of patients with symptomatic coronavirus disease 2019 (COVID-19) may need admission to intensive care units (ICUs) because of severe respiratory failure, requiring mechanical invasive ventilation [2,3]. Open space systems have been suggested...
as a way of cohorting patients with COVID-19 in order to improve direct patient care, reduce the number of personal protective equipment (PPE) used and the risk of contamination of healthcare personnel during donning and doffing [4]. However, the protective measures applied to patients with COVID-19 often do not have the main aim of preventing cross-transmission of pathogens between hospitalized patients. Before the current pandemic, the emergence of antimicrobial resistance among bacteria and fungi has been one of the worldwide leading threats [5–9]. To minimize the impact of antimicrobial resistance, adequate antimicrobial stewardship programs have been recommended, as well as implementation of infection control measures, based on active screening for colonization with resistant pathogens and strict contact isolation precautions for carriers to avoid horizontal spread among patients [10]. Optimizing antimicrobial prescription might be challenging among COVID-19 patients, especially critical ones, since clinical severity, imaging features and laboratory parameters make it difficult to differentiate bacterial co-infection from the mere effects of SARS-CoV-2. Likewise, implementing measures to limit the spread of resistant pathogens [11] might be particularly difficult in settings like those of COVID-19 ICUs.

The aim of this study was to report our experience with selection and subsequent cross-transmission of drug-resistant pathogens between COVID-19 patients admitted to the ICU.

2. Materials and Methods

2.1. Study Setting and Population

San Martino Policlinico Hospital–IRCCS is a 1200-bed university reference hospital in Genoa, Italy, that was chosen as regional hub for the most complex cases of COVID-19 at the beginning of the pandemic. During the pandemic, three COVID-19 dedicated ICUs were organized: one with 27 beds opened throughout the study period; a second with 12 beds opened specifically to face the pandemic on 18 March 2020 and closed on 18 April 2020 when the number of COVID-19 cases slowly decreased; and a third temporary ICU with 8 beds, which was not included in the present study. Data of all COVID-19 patients admitted to the first two ICUs during the study period between 28 February and 31 May were reviewed in order to identify the presence of drug-resistant organisms. Demographic, clinical and microbiological data were retrieved from electronic charts. Data on patients admitted to the ICU in the previous trimester (1 December 2019 to 27 February 2020) were also retrieved to allow for a descriptive comparison. During that period only the bigger ICU with 27 beds was operative.

2.2. Center-Specific Protocols

All patients with severe COVID-19 admitted to our hospital received antibiotic treatment against bacterial pulmonary super-/co-infection with a fifth-generation cephalosporin. Before the COVID-19 pandemic, infectious disease (ID) consultation at the ICU was provided according to clinical judgement of treating clinicians, while after the start of the pandemic the ID consultation service was potentiated, with a team of designated ID specialists providing daily consultations to support ICU colleagues with microbiological diagnosis and antimicrobial prescription. San Martino Policlinico Hospital–IRCCS infection control policy requires that all patients admitted to the ICU undergo weekly rectal swabs for the detection of carbapenem-resistant Enterobacterales (CRE) colonization. After identification of the first two cases of C. auris infection, screening swabs of the groin, axillary and auricular area to detect asymptomatic Candida colonization were carried out among all the patients admitted to the same ICU.

2.3. Microbiology and Definitions

Drug-resistant pathogens, for the scope of this study, were defined as carbapenem-resistant P. aeruginosa (CRPA) strains; carbapenem-resistant K. pneumoniae (CR-Kp), regardless of the molecular mechanism of resistance and all strains of C. auris. Resistance
to meropenem (minimum inhibitory concentration (MIC) ≥8 mg/L) was considered to
define carbapenem resistance for both CRPA and CR-Kp [12]. Antimicrobial susceptibility
to carbapenems, aminoglycosides, fluoroquinolones and anti-pseudomonal β-lactams
(including ceftolozane/tazobactam) were tested for all the strains of P. aeruginosa isolated.
Currently, no species-specific susceptibility breakpoints are available for C. auris. Therefore,
susceptibilities were interpreted according to the tentative breakpoints proposed by the US
Centers for Disease Control and Prevention [13]. All C. auris strains considered in our study
proved resistant to amphotericin B, and further susceptibility to azoles and echinocandins
was tested. Apart from screening swabs, microbiological samples were collected upon
clinical suspicion of infection. Microorganism cultured from blood, respiratory or urinary
samples were identified using MALDI-TOF mass spectrometry (Vitek MS; bioMérieux,
Craponne, France). Antimicrobial susceptibility testing was performed using the Vitek2
system (Biomerieux, Craponne, France), while antifungal testing was carried out by means
of the Clinical and Laboratory Standards Institute microdilution method and the Sensititre
YeastOne panel (Thermo Scientific, Waltham, MA, US). C. auris clonal relatedness was
evaluated by means of whole genome sequencing (Qiagen DNeasy PowerLyzer PowerSoil
Kit; Qiagen, Hilden, Germany). Given the rarity of primary Candida pneumonia, all isolates
of C. auris in respiratory samples were considered as colonizers [14]. Microbiological eradi-
cation was defined as negativity of follow-up cultures alongside clinical and laboratory
improvement, while clinical cure was defined as clinical improvement without evidence of
microbiological eradication.

2.4. Endpoint

The primary endpoint was acquisition of colonization and development of infection
with CRPA, C. auris and CR-Kp among COVID-19 patients admitted to the ICUs.

3. Results

3.1. Study Population

From 28 February to 31 May 118 patients were admitted to the COVID-19 ICUs in our
hospital. Overall, the median ICU stay was 17 days (IQR 8–27 days), 74.6% of patients
(n = 88) were male and median age was 71 years (IQR 65–78 years). The median age-
adjusted Charlson Comorbidity Index was 3 (IQR 2–4). Crude in-ICU mortality observed
during the study period was 42.4% (n = 50). Median ICU stay in the 27-bed ICU was
18 days (IQR 9–32 days) and 21 days (IQR 13–29 days) in the 12-bed ICU.

3.2. Colonization or Infection Rate with Resistant Organisms in COVID-19 ICU and Descriptive
Comparison with Pre-COVID-19 Period

Overall, 14 patients were included in the present study, of whom 12 (10.2%) were
colonized or infected with CRPA, 6 (5.1%) with C. auris and 2 (1.6%) with CR-Kp. Col-
onization or infection with resistant pathogens was observed mainly in the 27-bed ICU,
where 92 patients were admitted, 13% (n = 12) were colonized or infected with CRPA, 6.5%
(n = 6) with C. auris and 1.1% (n = 1) with CR-Kp. In the 12-bed ICU only one patient
with pre-existing CR-Kp colonization was admitted. Among colonized/infected patients,
median time from admission to first detection of resistant organism was 18 days (IQR
16–20 days), specifically 18 days (IQR 16–20 days) for CRPA and 38 days (IQR 26–41 days)
for C. auris. The only newly acquired CR-Kp infection developed after 20 days of ICU
stay. Demographics, comorbidities, sites of colonization/infection and outcomes of the
14 patients are outlined in Table 1. During the trimester prior to the COVID-19 pandemic,
159 patients were admitted to the 27-bed ICU, 56.6% of which were males (n = 90), with
a median age of 66 years (IQR 52–75 years). The median ICU stay was 7 days (IQR 3–16
days) and crude in-ICU mortality was 13.2% (n = 21). During that period, four patients
(2.5%) were colonized or infected with CRPA after a median of 35 days (IQR 28–47 days)
and five patients (3.1%) with CR-Kp after a median of 4 days (IQR 1–13 days). No episodes
of C. auris colonization or infection were documented, but one patient who was admitted
to the ICU in February 2020 developed *C. auris* colonization 3 days after being transferred from the ICU to the surgery ward. Three of four patients (75%) with CRPA and three of five patients (60%) with CR-Kp developed infection without prior colonization.

### 3.3. Carbapenem-Resistant *P. aeruginosa*

The first case of CRPA infection (a lung abscess) was diagnosed on 3 April, and nine out of 11 subsequent infections developed within one month (Table 1). Almost all patients (11/12, 91.7%) had CRPA infection, while one patient, colonized at the site of previous vascular access, died shortly after isolation without developing CRPA infection. All patients with CRPA received prior meropenem therapy, with a median duration of 5 days (range 4–22 days) and within a median of 9 days from admission to the ICU (IQR 5–11 days). This consisted of an empirical treatment of a suspected bacterial superinfection in 75% of cases (n = 9), while the remaining three patients (25%) received meropenem for the treatment of a ventilator-associated pneumonia due to *P. aeruginosa*, and two episodes of bloodstream infection due to, respectively, *P. aeruginosa* and extended-spectrum β-lactamases producing *E. coli*. At baseline level, aminoglycoside resistance was detected in two patients (16.7%), fluoroquinolone resistance in four (33.3%), ceftazidime resistance in five (41.7%), resistance to piperacillin/tazobactam in six (50%) and resistance to ceftolozane/tazobactam in two (16.7%). Of note, four patients (33.3%) presented selective resistance to carbapenems, with retained susceptibility to all other antimicrobials. These patients had been treated for a median of 8 days (IQR 7–12) with meropenem. Moreover, 33% (three out of nine) of the patients who received ceftolozane/tazobactam as treatment, alone or as part of combination therapy, for a median of 21 days (IQR 15–42 days) developed resistance to this drug during or after treatment. Crude mortality among CRPA patients was 41.7% (n = 5) after a median of 42 days (IQR 25–51 days) from first detection of infection. Attributable mortality, according to caring clinicians’ judgement, was estimated to be 16.7% (n = 2).

### 3.4. *C. auris*

The first patient with *C. auris* respiratory colonization died after 8 days of ICU stay and prior to complete culture results. The subsequent two patients were diagnosed with *C. auris* respiratory tract colonization 28 and 33 days later. The screening of patients concomitantly admitted to the ICU identified three more patients colonized with *C. auris* within the following month. All the patients colonized/infected with *C. auris*, except for the first patient, received long courses of broad-spectrum antibiotics for bacterial infections before being diagnosed with *C. auris* colonization. Overall, four patients were diagnosed with *C. auris* candidemia: one with no prior colonization and three of six colonized patients (after 4, 5 and 44 days from colonization onset). All patients colonized/infected with *C. auris*, except for the first patient, were concomitantly colonized/infected with CRPA. All strains of *C. auris* identified proved to be resistant to amphotericin-B and azoles but susceptible to echinocandins. Among patients with candidemia, we report a 50% (n = 2) mortality after 25 days from first *C. auris* isolation. Whole genome sequencing of the strains isolated demonstrated close genetic relatedness of the strains, consistent with nosocomial transmission of the pathogen.

### 3.5. Carbapenem-Resistant *K. pneumoniae*

Among the two patients colonized with CR-Kp, one was a transplant recipient patient with a known CR-Kp colonization who developed ventilator-associated pneumonia caused by this colonizing strain. The other patient with CR-Kp, who had received previous empirical meropenem therapy for 20 days, developed multimicrobial ventilator-associated pneumonia with both CR-Kp and CRPA. Both CR-Kp isolates showed a multi-drug-resistant phenotype (i.e., resistant to at least three classes of antimicrobials). Observed mortality was 50% (n = 1) after 26 days from development of CR-Kp infection, although this was not primarily attributable to this pathogen.
Table 1. Demographics, comorbidities, sites of drug-resistant organisms’ colonization/infection and outcomes of the 14 patients described in the study.

| Patient ID | Sex | Age | Comorbidities                          | Pathogen Isolated | Date of First Isolation | Time from ICU Admission to First Isolation | Antimicrobial Susceptibility Profile | Site of Isolation | Subsequent Infection, Type | Time from First Isolation to Infection, Days | Treatment, Drug and Duration | Microbiological Outcome at the End of Study Period | Outcome at the Last Follow-Up (Days After the First Isolation) |
|------------|-----|-----|----------------------------------------|-------------------|------------------------|-------------------------------------------|-------------------------------------|------------------|-----------------------------|-----------------------------------------------|--------------------------------|---------------------------------------------|-------------------------------------------------|
| 1          | M   | 70  | Type 2 diabetes mellitus, obesity      | C. auris          | 19 March               | 8                                         | -                                   | BAL              | No                          | N/A                                           | N/A                                         | N/A                                         | Death (same day)                                   |
| 2          | M   | 52  | Hypertension                           | CRPA              | 3 April                | 19                                        | AMG S, FQ S, CAZ S, P/T S, C/T S       | BAL              | Yes, lung abscess           | 0                                             | C/T, 42 days                                   | Clinical cure                                 | Alive, discharged from ICU (26 days)             |
| 3          | M   | 51  | Hypertension                           | CRPA              | 9 April                | 15                                        | AMG R, FQ R, CAZ R, P/T R, C/T R        | BAL              | Yes, VAP                    | 0                                             | HD meropenem + i.v. colistin + i.v. fosfomycin, 14 days | Clinical cure                                 | Alive, discharged from ICU (12 days)              |
| 4          | F   | 57  | Hyperthyroidism                        | CRPA              | 9 April                | 16                                        | AMG S, FQ S, CAZ S, P/T S, C/T S        | Sputum           | Yes, VAP                    | 0                                             | C/T, 16 days                                   | Clinical cure                                 | Death (60 days)                                  |
| 5          | M   | 67  | Type 2 diabetes mellitus, COPD         | CRPA              | 12 April               | 16                                        | AMG S, FQ S, CAZ S, P/T S, C/T S        | BAL              | Yes, BSI                    | 2                                             | C/T, 14 days                                   | Microbiological eradication                   | Alive, discharged from ICU (16 days)             |
| 6          | M   | 62  | None                                   | CRPA              | 17 April               | 19                                        | AMG S, FQ S, CAZ S, P/T S, C/T S        | Pleural fluid    | Yes, plural empyema and lung abscess | 0                                             | C/T + i.v. fosfomycin + HD amikacin + nebulized colistin, 42 days | Persistence of infection                        | Alive, still admitted to ICU (>160 days from CRPA) |
|            |     |     |                                        |                   | 13 May                  | 45                                        | Surveillance swab                       | Yes, BSI         | 44                          |                                               | Caspofungin, 48 days                           | Microbiological eradication                   |                                                 |
| 7          | M   | 69  | CAD                                    | CRPA              | 18 April               | 16                                        | AMG S, FQ S, CAZ S, P/T S, C/T S        | BAL              | Yes, lung abscess           | 0                                             | C/T + nebulized colistin, 48 days; then cefiderocol 3 days | Persistence of infection                        | Death (51 days from CRPA, 26 from C. auris) * |
|            |     |     |                                        |                   | 13 May                  | 41                                        | Surveillance swab                       | Yes, BSI         | 4                           |                                               | Caspofungin, 19 days; then amphotericin B 7 days | Microbiological eradication                   |                                                 |
| Patient ID | Sex | Age | Comorbidities                      | Pathogen Isolated | Date of First Isolation | Time from ICU Admission to First Isolation | Antimicrobial Susceptibility Profile | Site of Isolation | Subsequent Infection, Type | Time from First Isolation to Infection, Days | Treatment, Drug and Duration | Microbiological Outcome at the End of Study Period | Outcome at the Last Follow-Up (Days After the First Isolation) |
|------------|-----|-----|-----------------------------------|-------------------|-------------------------|-------------------------------------------|-------------------------------------|------------------|----------------------------|------------------------------------------|-------------------------------------------|-----------------------------------------------|-----------------------------------------------------|
| 8          | M   | 50  | None                              | CRPA              | 20 April                | 15                                        | AMG S, FQ S, CAZ R, P/T R, C/T S       | BAL              | Yes, VAP                  | 0                                        | C/T, 21 days                               | Clinical cure                                 | Alive, discharged from ICU (24 days from CRPA; 1 day from C. auris) |
| 96         | M   | 66  | OLT, epilepsy                      | CR-Kp             | 1 April                 | 0                                         | Surveillance swab                     | Surveillance swab | Yes, VAP                  | 1                                        | CAZ/AVI + i.v. fosfomycin, 15 days          | Clinical cure                                 | Alive, discharged from ICU (86 days)            |
| 10         | M   | 62  | Hypertension                       | CRPA              | 22 April                | 30                                        | AMG S, FQ S, CAZ S, P/T S, C/T S       | BAL              | Yes, VAP                  | 0                                        | C/T, 15 days                               | Clinical cure                                 | Alive, discharged from ICU (40 days from CRPA; 46 from C. auris) |
| 11         | M   | 64  | Hypertension, asthma               | CRPA              | 27 April                | 10                                        | AMG S, FQ S, CAZ S, P/T R, C/T S       | BAL              | Yes, BSI and lung abscess| 0                                        | C/T + amikacin + i.v. fosfomycin, 28 days    | Persistence of infection                      | Death (42 days from CRPA; 48 days from C. auris) |
| 12         | M   | 65  | Hypertension, OSAS                 | CRPA              | 3 May                   | 23                                        | AMG S, FQ R, CAZ R, P/T R, C/T S       | Blood culture     | Yes, BSI                  | 0                                        | C/T + gentamycin, 14 days                  | Microbiological eradication                  | Alive, discharged from ICU (56 days)            |
| 13         | M   | 63  | CVI                                | CRPA              | 18 May                  | 19                                        | AMG R, FQ R, CAZ R, P/T S, C/T R       | BAL              | Yes, VAP                  | 0                                        | CAZ/AVI + i.v. colistin + nebulized colistin, 15 days | Persistence of infection                      | Death (25 days from CRPA, 26 days from CR-Kp) |
| 14         | F   | 67  | CAD, hypothyroidism                | CRPA              | 21 May                  | 55                                        | AMG S, FQ R, CAZ R, P/T S, C/T S       | Wound swab        | No                         | N/A                                      | N/A                                       | N/A                                           | Death (2 days)                                 |

AMG, aminoglycoside; FQ, fluoroquinolones; CAZ, ceftazidime; P/T, piperacillin/tazobactam; C/T, ceftolozane/tazobactam; CAZ/AVI, ceftazidime/avibactam; HD, high dose; COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnea syndrome; CAD, coronary artery disease; OLT, orthotopic liver transplant; CVI, common variable immunodeficiency; CRPA, carbapenem-resistant *P. aeruginosa*; BAL, bronchoalveolar lavage; VAP, ventilator-associated pneumonia; BSI, bloodstream infection; ICU, intensive care unit; N/A: not applicable. § Patient only admitted to the 12-bed ICU; * death possibly related to CRPA infection.
4. Discussion

In this paper we present real-life data on high rate of colonization/infection with carbapenem-resistant *P. aeruginosa* (CRPA) and a nosocomial outbreak of *C. auris* occurring in one of the COVID-19 dedicated ICUs at our hospital. A low rate of carbapenem-resistant *K. pneumoniae* isolation was noted.

In our setting, CRPA had the most negative impact, with 10.2% of patients admitted to two COVID-19 ICUs acquiring CRPA and almost all of them developing invasive infection. Although all the cases occurred within a short period of time, it was not possible to document horizontal cross-transmission due to lack of CRPA clonality data and the impossibility of ruling out the role of selective pressure of prior treatment with meropenem. On the contrary, given the epidemiology and clonal relatedness of *C. auris* strains in our hospital, the hypothesis of nosocomial outbreak is plausible.

We speculated on possible reasons for the observation of an outbreak and a possible cluster of carbapenem-resistant pathogens. We observed a longer median ICU stay when compared to the trimester prior to the pandemic (17 vs. 7 days) and higher in-ICU crude mortality (42.4% vs. 13.2%), suggesting the clinical complexity of these patients, more prone to acquisition of nosocomial infections. Moreover, we postulated a negative impact of COVID-19 on antimicrobial stewardship programs, an issue reported in a speculative manner in various reviews and editorials. To the best of our knowledge, only one real-life report describes the acquisition of CR-Kp colonization among COVID-19 patients [15], while two centers reported an increase in *C. auris* infections in COVID-19 patients [16,17]. We supposed that the main drivers of an increase in antimicrobial resistance during COVID-19 in our hospital were the use of broad-spectrum antimicrobials and horizontal spread of resistant strains. Wide prescription of broad-spectrum antibiotics might be attributed to the difficulty of differentiating among pulmonary bacterial co-infection and viral infection alone in febrile patients with radiological evidence of mixed consolidative and interstitial patterns [18–20]. Moreover, the severity of clinical conditions in a setting with a high rate of extended-spectrum beta-lactamases producing bacteria might contribute to the extensive use of carbapenems for empirical therapy [21]. In addition, contact isolation measures might be suboptimal due to several reasons. First, in COVID-19 ICUs, the use of open spaces has been preferred to permit an easier management of a high number of patients [4], increasing the potential for horizontal transmission. Second, in COVID-19 units, donning with PPE is mostly focused on the protection of healthcare personnel from viral infection, with less attention to avoiding pathogen transmission between patients, who were usually not considered at risk for harboring resistant bacteria, since most of the SARS-CoV-2 infections were community-acquired. Third, despite good clinical practice recommendations, this uncomfortable PPE might be seldom renewed when caring for different patients in open spaces to limit the risk for personnel contamination during undressing and, in some cases, due to PPE shortage. Fourth, the persistence of resistant pathogens in the environment of the ICU, despite applied contact precaution measures, could not be excluded.

Despite the increase in resistant pathogens, crude mortality among critically ill patients in our ICUs was lower than that observed in other Italian centers [22] or in large international cohorts of COVID-19 patients admitted to ICUs during the early period of the pandemic [23,24].

The main limitations of this study are its retrospective design and the lack of clonality data for CRPA and CR-Kp. Additionally, a descriptive comparison with pre-COVID-19 data might be biased given various clinical profiles of patients admitted to the ICU prior to the pandemic, compared to the more homogenous population of COVID-19 ICU patients who needed longer ICU care.

5. Conclusions

Our report is one of the first to provide real-life data on possible selection and transmission of drug-resistant organisms among critically ill COVID-19 patients. It highlights
the need for further studies to determine the precise impact of COVID-19 on antimicrobial stewardship and infection control and to develop adequate strategies to prevent further spread of antimicrobial resistance.

**Author Contributions:** Conceptualization, L.M. and M.M. and D.R.G.; methodology, M.M. and D.R.G.; software, L.M.; validation, M.M.; formal analysis, L.M.; investigation, L.M. and D.R.G. and L.T. and A.V. and C.D. and C.R. and L.B. and N.P.; resources, F.C. and E.C. and G.C. and A.M.; data curation, S.D. and S.T. and L.L. and V.D.P.; writing—original draft preparation, L.M. and M.M.; writing—review and editing, L.M. and M.M. and D.R.G. and L.T. and P.P.; supervision, P.P. and M.B.; project administration, M.M. and M.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** The study was approved by the Ethics Committee of the Liguria region (N. CER Liguria 163/2020).

**Informed Consent Statement:** A waiver of informed consent for patients unable to provide an informed consent was granted in view of the retrospective nature of the analyses.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy issues.

**Acknowledgments:** Anna Alessandrini, Marco Camera, Emanuele Delfino, Andrea De Maria, Chiara Dentone, Antonio Di Biagio, Ferdinando Dodi, Antonio Ferrazin, Giovanni Mazzarello, Malgorzata Mikulska, Laura Nicolini, Federica Toscanini, Daniele Roberto Giacobbe, Antonio Vena, Luca Tarasasso, Elisa Balletto, Federica Fortunato, Eva Schenone, Nirmala Rossetti, Federico Baldi, Marco Berruti, Federica Briano, Silvia Dettori, Laura Labate, Laura Magnasco, Michele Mirabella, Rachele Pincino, Chiara Russo, Giovanni Sarteschi, Chiara Sepulcri, Stefania Tutino (Clinica di Malattie Infettive); Roberto Pontremoli; Valentina Beccati; Salvatore Casciaro; Massimo Casu; Francesco Gavaudan; Maria Ghinatti; Elisa Gualco; Giovanna Leoncini; Paola Pitt; Kassem Salam (Clinica di Medicina Interna 2); Iole Brunetti, Maurizio Loconte, Maria Rita De Rito, Roberta Pasce, Manuela Cerana, Arduino Lumeno De Lucia, Giovanna Politi, Alexandre Molin, Chiara Berri, Roberto Pesce, Andrea Fedele, Paola Perrini, Angelo Insorsi, Fabio Tarantino, Alessandra Canepa, Giordano Rossetti, Federico Piccardo, Alessandro Accattatis, Domenico De Lisi, Marcus Ferretti, Denise Battaglini (Clinica Anestesiologica e Terapia Intensiva); Angelo Gratarola; Mattia Bixio; Annalisa Amelia; Andrea Balestra; Paola Ballarino; Nicholas Bardi; Roberto Boccafogli; Francesca Caserza; Elisa Calzolari; Marta Castelli; Elisabetta Cenni; Paolo Cortese; Giuseppe Cuttin; Sara Feltrin; Stefano Gioviano; Patrizia Giuntini; Letizia Natale; Davide Orsi; Matteo Pastori; Tommaso Perazzo; Fabio Pescetelli; Federico Schenone; Maria Grazia Serra; Marco Sottano (Anestesia e Rianimazione; Emergenza Covid padiglione 64 “Fagiolone”); Roberto Tallone; Massimo Amelotti; Marie Jeanne Majab; Massimo Merlioni; Federica Perazzo (Cure intermedie); Nidal Ahamd; Paolo Barbera; Marta Bovio; Paola Campodonico; Andrea Collidi; Ombretta Cutuli; Agnese Lomeo; Francesca Fezza; Nicola Gentilucci; Nadia Hussein; Emanuele Malvezzi; Laura Massobrio; Maria Grazia Piroddi; Elisa Russo; Giovanni Battaglini; Giancarlo Sartini (Dipartimento di Emergenza ed accettazione); Italo Porto; Giampaolo Bezante; Roberta Della Bona; Giovanni La Malfa; Alberto Valbusa; Vered Gil Ad (Clinica Malattie Cardiovascolari); Emanuela Barisione; Michele Bellotti; Aloe Teresita; Alessandro Blanco; Marco Grosso; Maria Grazia Pirotti; Maria Grazia Pirotti (Pneumologia ad Indirizzo Interventistico); Paola Moscatelli; Paola Ballarino; Matteo Caiti; Elisabetta Cenni; Patrizia Giuntini; Ottavia Magnani (Medicine d’Urgenza); Simir Sukkar; Ludovica Cogorno; Raffaella Gradaschi; Erica Guido; Eleonora Martino; Livia Piscotta (Dietetica e nutrizione clinica); Bruno Cavagliere; Rossi Cristina; Farina Francesca (Direzione delle Professioni Sanitarie); Giacomo Garibotto; Pasquale Esposito; Francesca Viazzi; Michela Saio; Elisa Russo; Giovanni Battista Traverso (Clinica nefrologica, dialisi e trapianto); Giovanni Passalacqua; Diego Bagnasco; Fulvio Braid; Annamaria Riccio; Elena Tagliabue (Clinica Malattie Respiratorie ed Allergologia); Claudio Gustavino; Antonella Ferraiolo (Ostetricia e Ginecologia); Salvatore Giffrida; Nicola Rosso (Direzione Amministrativa); Alessandra Morando; Riccardo Papalia; Donata Passerini; Gabriella Tiberio (Direzione di presidio); Giovanni Orengo; Alberto Battaglini (Gestione del rischio clinico); Silvano Ruffoni; Sergio Caglieris (Servizio emergenza 118 e 112).
Conflicts of Interest: Outside the submitted work, MM has received personal fees from Gilead, Pfizer, Merck, Biotest and Janssen; DRG reports honoraria from Stepstone Pharma GmbH and unconditional grants from MSD Italia and Correvio Italia; MB has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, Bayer, Basilea, BioMérieux, Cidara, Gilead, Menarini, MSD, Nabreva, Paratek, Pfizer, Roche, Melinta, Shionogi, Tetraphase, VenatoRx and Vifor and has received study grants from Angelini, Basilea, Astellas, Shionogi, Cidara, Melinta, Gilead, Pfizer and MSD. The other authors have no conflicts of interest to disclose.

Abbreviations

AMG, aminoglycoside; FQ, fluoroquinolones; CAZ, ceftazidime; P/T, piperacillin/tazobactam; C/T, ceftolozane/tazobactam; CAZ/AVI, ceftazidime/avibactam; HD, high dose; COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnea syndrome; CAD, coronary artery disease; OLT: orthotopic liver transplant; CVI, common variable immunodeficiency; CRPA, carbapenem-resistant P. aeruginosa; CR-Kp; carbapenem-resistant Klebsiella pneumoniae; BAL, bronchoalveolar lavage; VAP, ventilator-associated pneumonia; BSI, bloodstream infection; ICU, intensive care unit; N/A: not applicable; SARS-CoV-2, severe acute respiratory distress coronavirus-2; COVID-19, coronavirus disease 2019; PPE, personal protective equipment; CRE, carbapenem-resistant Enterobacteriales; ID, infectious disease.

References

1. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020, 382, 727–733. [CrossRef] [PubMed]
2. Wu, Z.; McGoogan, J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020, 323, 1239–1242. [CrossRef] [PubMed]
3. Goyal, P.; Choi, J.J.; Pinheiro, L.C.; Schenck, E.J.; Chen, R.; Jabri, A.; Satlin, M.J.; Campion, T.R., Jr.; Nahid, M.; Ringel, J.B.; et al. Clinical Characteristics of Covid-19 in New York City. N. Engl. J. Med. 2020, 382, 2372–2374. Available online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182018/ (accessed on 3 January 2021). [CrossRef] [PubMed]
4. Phua, J.; Weng, L.; Ling, L.; Egi, M.; Lim, C.M.; Diviatia, J.V.; Shrestha, B.R.; Arabi, Y.M.; Ng, J.; Comersall, C.D.; et al. Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations. Lancet Respir. Med. 2020, 8, 506–517. [CrossRef]
5. World Health Organization. Global Action Plan on Antimicrobial Resistance. S. Afr. Med. J. 2015, 105, 325. [CrossRef] [PubMed]
6. World Health Organization. No Time to Wait: Securing the Future from Drug-Resistant Infections. Report to the Secretary-General of the United Nations. April 2019. Available online: http://www.who.int/antimicrobial-resistance/interagency-coordination-group/final-report/en/ (accessed on 10 December 2020).
7. French, C.E.; Coope, C.; Conway, L.; Higgins, J.P.; McCulloch, J.; Okoli, G.; Patel, B.C.; Oliver, I. Control of carbapenemase-producing Enterobacteriaceae outbreaks in acute settings: An evidence review. J. Hosp. Infect. 2017, 95, 3–45. [CrossRef] [PubMed]
8. Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter Baumannii and Pseudomonas Aeruginosa in Health Care Facilities [Internet]; (WHO Guidelines Approved by the Guidelines Review Committee); World Health Organization: Geneva, Switzerland, 2017. Available online: http://www.ncbi.nlm.nih.gov/books/NBK493061/ (accessed on 8 September 2020).
9. Spivak, E.S.; Hanson, K.E. Candida auris: An Emerging Fungal Pathogen. J. Clin. Microbiol. 2018, 56, e01588-17. [CrossRef] [PubMed]
10. Karampatakis, T.; Tsergouli, K.; Iosifidis, E.; Antachopoulos, C.; Karapanagiotou, A.; Karyoti, A.; Gritsi-Gerogianni, N.; Tsakris, A.; Roilides, E. Impact of active surveillance and infection control measures on carbapenem-resistant Gram-negative bacterial colonization and infections in intensive care. J. Hosp. Infect. 2018, 99, 396–404. [CrossRef] [PubMed]
11. Minimum Requirements for Infection Prevention and Control; Licence: CC BY-NC-SA 3.0 IGO; World Health Organization: Geneva, Switzerland, 2019.
12. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0. 2021. Available online: http://www.eucast.org (accessed on 3 January 2020).
13. Centre for Diseases Control and Prevention. Available online: https://www.cdc.gov/fungal/diseases/candidiasis/recommendations.html (accessed on 10 December 2020).
14. Pendleton, K.M.; Huffnagle, G.B.; Dickson, R.P. The significance of Candida in the human respiratory tract: Our evolving understanding. Pathog. Dis. 2017, 75, ttx029. [CrossRef] [PubMed]
15. Tiri, B.; Sensi, E.; Marsiliani, V.; Cantarini, M.; Priante, G.; Verneli, C.; Martella, L.A.; Costantini, M.; Mariotti, A.; Andreani, P.; et al. Antimicrobial Stewardship Program, COVID-19, and Infection Control: Spread of Carbapenem-Resistant Klebsiella Pneumoniae Colonization in ICU COVID-19 Patients. What Did Not Work? J. Clin. Med. 2020, 9, 2744. [CrossRef] [PubMed]
16. Rodriguez, J.Y.; Le Pape, P.; Lopez, O.; Esquea, K.; Labiosa, A.L.; Alvarez-Moreno, C. Candida auris: A latent threat to critically ill patients with COVID-19. *Clin. Infect. Dis.* 2020, 18, ciaa1595. [CrossRef] [PubMed]

17. Chowdhary, A.; Tarai, B.; Singh, A.; Sharma, A. Multidrug-Resistant Candida auris Infections in Critically Ill Coronavirus Disease Patients, India, April-July 2020. *Emerg. Infect. Dis.* 2020, 26, 2694–2696. [CrossRef] [PubMed]

18. Rawson, T.M.; Moore, L.S.; Zhu, N.; Ranganathan, N.; Skolimowska, K.; Gilchrist, M.; Satta, G.; Cooke, G.; Holmes, A. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. *Clin. Infect. Dis.* 2020, 71, 2459–2468. [PubMed]

19. Rodriguez-Morales, A.J.; Cardona-Ospina, J.A.; Gutiérrez-Ocampo, E.; Villamizar-Peña, R.; Holguín-Rivera, Y.; Escalera-Antezana, J.P.; Alvarado-Arnez, L.E.; Bonilla-Aldana, D.K.; Franco-Paredes, C.; Henao-Martinez, A.F.; et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. *Travel Med. Infect. Dis.* 2020, 34, 101623. [CrossRef] [PubMed]

20. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. *Lancet* 2020, 395, 1054–1062. [CrossRef]

21. European Centre for Disease Prevention and Control. *Surveillance of Antimicrobial Resistance in Europe—Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017*; ECDC: Stockholm, Sweden, 2018.

22. Grasselli, G.; Greco, M.; Zanella, A.; Albano, G.; Antonelli, M.; Bellani, G.; Bonanomi, E.; Cabrini, L.; Carlesso, E.; Castelli, G.; et al. Risk Factors Associated with Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Intern. Med.* 2020, 180, 1345–1355. [CrossRef] [PubMed]

23. Richards-Belle, A.; Orzechowska, I.; Gould, D.W.; Thomas, K.; Doidge, J.C.; Mouncey, P.R.; Christian, M.D.; Shankar-Hari, M.; Harrison, D.A.; Rowan, K.M. COVID-19 in critical care: Epidemiology of the first epidemic wave across England, Wales and Northern Ireland. *Intensive Care Med.* 2020, 46, 2035–2047. [CrossRef] [PubMed]

24. Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; Barnaby, D.P.; Becker, L.B.; Chelico, J.D.; Cohen, S.L.; et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020, 323, 2052–2059, Erratum in *JAMA* 2020, 323, 209. [CrossRef] [PubMed]